Fuller H B (FUL) Q2 FY26 earnings call

A pricing-driven quarter: swift April increases and industry-leading sourcing turned petrochemical dislocation into share gains and margin expansion, even as volumes stayed soft and management guides cautiously for consumer-led H2 weakness. The defining move is the AMS offer — a portfolio up-tiering into higher-growth, higher-margin medical that lifts leverage near-term but is framed as a time-sensitive step toward the 20% margin goal.